EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients.
The European Academy of Paediatrics has warned the EU to correct a new law that inadvertently prevents the provision of essential medical devices for children, citing unintended consequences of the EU Medical Devices Regulation (MDR).
In a letter sent on June 27, 2023 to EU Health Commissioner Stella Kyriakides, the Academy, along with 22 other medical associations, cited that the law that requires companies to recertify their products. Though the deadline for companies to achieve this has been extended until 2027/2028, reports from doctors claim that the new legislation has caused shortages of certain lifesaving equipment, especially those from small drug device companies that cannot afford the new compliance procedure, and that the extension has not solved the issue for these companies. All drug device companies are required by the new law to sign a contract by September 2024 with a notified body to begin the recertification process. The law came into effect in 2021 with the goal of preventing health scandals.
The group cited one particular company that received invoices from a notified body of over EUR €800,000 for a single device to be assessed. The device is already on the market for, at the most, 5 years of market access. At nearly 150 times more costly than the process in the United States for the same device, the group warns that similar situations may cause lifesaving drug devices to disappear from the market. In the letter, the associated groups urged for access protection of certain drug devices for children and patients with rare diseases. They reported that a specific type of catheter utilised in lifesaving surgery on newborns with heart defects has become unavailable due to the law, as well as shortages in dialysis machines for children with kidney disease.
The group emphasised the dire consequences of such shortages in their letter, stating “This will result in an avoidable risk of death and serious injury – not as a consequence of unsafe medical devices, but as a consequence of [the] disappearance of devices due to unforeseen effects of the EU Medical Devices Regulation.”
Source: EU must prevent medical devices for children from disappearing, say doctors groups [Accessed June 28, 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/eu-must-prevent-medical-devices-children-disappearing-say-doctors-groups-2023-06-27/
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance